HPLC separation, synthesis, isolation and characterization of process related and degradation impurities in larotaxel including method development and validation

Synthesis and biological evaluation of novel larotaxel analogues

(2018) Sumei Ren et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Synthesis and Cytotoxicity of Two Active Metabolites of Larotaxel

(2016) Jianwei Li et al.   Anti-Cancer Agents in Medicinal Chemistry

Taxane anticancer agents: a patent perspective

(2015) Iwao Ojima et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Determination of larotaxel and its metabolites in rat plasma by liquid chromatography–tandem mass spectrometry: Application for a pharmacokinetic study

(2014) Zhenzhen Liu et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Isolation and characterization of process-related impurities and degradation products in larotaxel

(2011) Xin Che et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Randomized Multicenter Phase II Study of Larotaxel (XRP9881) in Combination with Cisplatin or Gemcitabine as First-Line Chemotherapy in Nonirradiable Stage IIIB or Stage IV Non-small Cell Lung Cancer

(2010) Petr Zatloukal et al.   Journal of Thoracic Oncology

Larotaxel: broadening the road with new taxanes

(2009) Otto Metzger-Filho et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy

(2008) V. Dieras et al.   ANNALS OF ONCOLOGY